Mye-EUNITER
 

Adema, Gosse

Research interests focus on the molecular analysis of professional antigen presenting dendritic cells and T-regulatory cells, and their function in the immune system in health and disease. Major current projects include i) functional analysis of DC-SCRIPT and Pattern Recognition Receptors in dendritic cell biology and ii) pre-clinical mouse studies on the role of dendritic cells and T-regulatory cells in immunotherapy of cancer and iii) development of immuno-combination therapies aiming to induce anti-tumor immune responses and to reverse the immune suppressive tumor microenvironment. The knowledge gathered in the fundamental immunological studies is translated into clinical vaccination studies of cancer patients with autologous, antigen-loaded dendritic cell vaccines.

Models available:

Dendritic cell immuno-biology, pattern recognition receptors, tumor microevironment, MDSCs, Macrophages, pre-clinical mouse studies on immunotherapy of cancer, development of immuno-combination therapies.

Cells available:

Dendritic cells, MDSCs, Macrophages

Technology available:

Research in mice and man. Animal models in cancer (melanoma, neuroblastoma, glioma) and inflammation (Candida, others). Human studies include glioma pts and Thyroid cancer pts as well as cohorts in infectious diseases (Candida etc).

Key publications related to Mye-EUNITER:

  1. Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, Klasen IS, Hilbrands LB, Figdor CG, de Vries IJ, Adema GJ. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res. 16:5067-78, 2010.
  2. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 2012 Jan;13(1):e32-42.
  3. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.Immunology. 2013 Feb;138(2):105-15.
  4. Oosting M, Cheng SC, Bolscher JM, Vestering-Stenger R, Plantinga TS, Verschueren IC, Arts P, Garritsen A, van Eenennaam H, Sturm P, Kullberg BJ, Hoischen A, Adema GJ, van der Meer JW, Netea MG, Joosten LA.Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4478-84.
  5. Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajanirefah A, Matarese F, Cheng SC, Ratter J, Berentsen K, van der Ent MA, Sharifi N, Janssen-Megens EM, Ter Huurne M, Mandoli A, van Schaik T, Ng A, Burden F, Downes K, Frontini M, Kumar V, Giamarellos-Bourboulis EJ, Ouwehand WH, van der Meer JW, Joosten LA, Wijmenga C, Martens JH, Xavier RJ, Logie C, Netea MG, Stunnenberg HG. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science. 2014 Sep 26;345(6204):1251086. doi: 10.1126/science.1251086.

Contact details:

Tumor Immunology
Geert Grooteplein 26-28
6525GA Nijmegen
The Netherlands
Tel. +31243617600
Gosse.Adema@RadboudUMC.nl